Pfizer Seeks Emergency Use Authorization for COVID-19 Oral Antiviral

Pfizer is seeking emergency use authorization (EUA) for its investigational COVID-19 oral antiviral PF-07321332/ritonavir (Paxlovid) for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death. The drug is a SARS-CoV-2 protease inhibitor that inhibits the viral replication of SARS-CoV-2 by blocking the activity of the SARS-CoV-2-3CL protease. If approved, it would be used during COVID-19 illness.

The oral antiviral was shown in a phase 2/3 clinical trial comparing safety and efficacy of Paxlovid to placebo in 1,219 patients with laboratory-confirmed SARS-CoV-2 infection within a 5-day period with mild to moderate symptoms. Patients had at least one characteristic or underlying condition associated with increased risk of developing severe illness from COVID-19.

Interim analysis of data showed that patients receiving Paxlovid treatment had a significantly greater reduction in the risk of COVID-19-related hospitalization or death from any cause within 3 days of symptoms onset compared with placebo. Similar findings were reported in patients treated within 5 days of symptom onset. There were no deaths reported in the Paxlovid arm of the study versus 10 deaths in the placebo arm.

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.